Assess whether the primary endpoint will survive FDA scrutiny (e7c4db)

SITUATION FDA Response and Labeling work in a 505(b)(2) program relying on literature plus a bridging study now turns on the primary endpoint will because a site-change that invalidates stability claims put CMC comparability package for a site change in play. RWE evidence-strategy director should say what CMC comparability package for a site change proves.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. RWE evidence-strategy director can defend Proceed under protocol from CMC comparability package for a site change after a site-change that invalidates stability claims in a Pharma & Life Sciences challenge. 2. RWE evidence-strategy director cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after a site-change that invalidates stability claims. 3. A site-change that invalidates stability claims never reached the population in CMC comparability package for a site change — reopen intake, do not close the primary endpoint will. 4. Two facts in CMC comparability package for a site change after a site-change that invalidates stability claims conflict for RWE evidence-strategy director; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read CMC comparability package for a site change against a site-change that invalidates stability claims and write the one fact that would move the primary endpoint will for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (CMC comparability package for a site change after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study.